Thymosin Alpha-1 protocol

Standard

32u

1.6 mg · 2×/week

FDA Zadaxin label: 1.6 mg twice weekly, 3–4 days apart.

Immune boost

32u

1.6 mg · Daily × 4 weeks

Intensive course.

Off

4 weeks

Essential break between cycles. Skipping leads to tolerance and diminishing returns.

Phase	How often	Dose	Units	Notes
Standard	2×/week	1.6 mg	32u	FDA Zadaxin label: 1.6 mg twice weekly, 3–4 days apart.
Immune boost	Daily × 4 weeks	1.6 mg	32u	Intensive course.
Off	4 weeks	–	–	Essential break between cycles. Skipping leads to tolerance and diminishing returns.

Cycle & timing

Cycle: 6–12 weeks on, 4 weeks off.

Timing: 2×/week SubQ, 3–4 days apart (Zadaxin label).

Where: SubQ abdomen.

What to expect

Immune improvement over 4–12 weeks. CD4/CD8 ratio and NK counts are measurable endpoints. Very well tolerated – one of the safest immune peptides available.

How much to buy

For 6-wk @ 1.6 mg × 2/wk:

4

× 5mg vials

2

× 10mg vials

Men & women

Unisex immune modulator, same protocol for men and women / protocol, no cycle effect; used in both sexes clinically. Avoid in pregnancy.

Dilution calculator

Set to the guide's typical mix for Thymosin Alpha-1. Change anything to see where to draw.

Vial size

BAC water added

Dose you want

Draw to

32u

Volume

0.32 mL

Strength

5 mg/mL

Doses per vial

3

Assumes a U-100 insulin syringe (100 units = 1 mL). Double-check against the compound's page before you draw.

Recommended mixes

Vial	Water	Strength
5 mg	1 mL	5 mg/mL
10 mg	2 mL	5 mg/mL

5 mg: 1 unit = 0.05 mg

Storage

PowderFreeze-dried: -4°F.
MixedReconstituted: 36–46°F, use within 4 weeks.

Don't use if: Active autoimmune flare · Severe immunosuppression therapy

Stop if you notice

Autoimmune flare, new immune-mediated symptoms

Side effects

Generally very well tolerated. Rare: injection-site reactions.

Drug interactions

Immunosuppressants (cyclosporine, tacrolimus, sirolimus, mycophenolate, methotrexate): pharmacologically opposed; T1 augments T-cell function while these suppress it. Combining is generally inappropriate outside a specialist-supervised protocol. Corticosteroids (chronic systemic): blunt the T1 immune response; coordinate dosing or pause steroids during a T1 course where clinically possible. Live vaccines: theoretical augmented response, coordinate timing with the prescriber. TNF-alpha inhibitors and other biologics (adalimumab, etanercept, infliximab, rituximab): mechanistically opposed for autoimmune indications; not advisable to combine without specialist oversight. Antiviral therapy for hepatitis B/C: T1 is studied as adjunct (Zadaxin label uses it that way), synergistic, not antagonistic.

Labs

Compound-specific: T-cell panel CD3/CD4/CD8/NK (baseline + post-course)

What these labs mean →

Warnings

FDA placed thymosin alpha-1 on the 2023 503A “may not be compounded” list (verify current status). Approved as Zadaxin in 35+ countries but not in the US.

Patient education

Used clinically as an adjunct to antiviral therapy for chronic hepatitis B and C in countries where Zadaxin is approved. Cyclic dosing (typically 1.6 mg SubQ 2× weekly for 4–12 weeks) is the canonical pattern; continuous dosing isn’t supported by the literature. Quality and authenticity vary widely in the US compounding market, verify supplier and request COA. Stop and contact a clinician for any new joint pain, rash, fevers, or symptoms suggesting an autoimmune flare.

These apply on top of the universal safety rules.

Pairs well with

CJC-1295 No DAC + Ipamorelin

recovery + immune stack

CJC-1295 (No DAC) + Ipamorelin

BPC-157 / TB-500

tissue repair

BPC-157 TB-500 (Thymosin Beta-4)

Epithalon

longevity

Epithalon

NAD+

mitochondrial immune support

NAD+

Glutathione

antioxidant

Glutathione

GHK-Cu

skin/immune repair

GHK-Cu

Avoid with

Active autoimmune flare

immune amplification may worsen

Severe immunosuppression therapy

interaction

Can Thymosin Alpha-1 + CJC-1295 (No DAC) + Ipamorelin share a syringe?

Can share a syringe. Both are water-based. Combine them if you dose on the same schedule and site.

Changes from the guide

The guide contradicted itself or had a slip here, so this page differs from the PDF:

Removed a stray editing note from the guide ("Source previously read 3x/week.").

What it does

Approved in 35+ countries (as Zadaxin); not approved in the US. FDA placed it on the 2023 503A “may not be compounded” list (verify current status).

Master immune regulator – approved in 35+ countries for hepatitis, cancer, and immune deficiency. Promotes T-cell differentiation. Activates dendritic cells, NK cells, and cytotoxic T-lymphocytes. Modulates Th1/Th2 balance.

References

researchdosing peptidedosages PubMed thepeptidereport peptides.id

From the guide, page 98.